title: [Current research advance on cellular immunotherapy for leukemia-review].
abstract: Despite the chemotherapy is successful in inducing remission of hematologic malignancy, this disease also has a high probability of relapse; besides, the toxicity of chemotherapy for these patients can not be avoided. Researchers have been attempting to eliminate tumor cells by immunotherapy. Recently, various leukemia-associated antigens (LAA) that are recognized by cytotoxic T cell (CTL) in the context of HLA class I molecules have been identified. These LAA include WT1, PR-3, RHAMM, BCR-ABL and Aur-A. On the basis of these findings, various clinical trials of immunotherapy for hematologic malignancy including tumor peptide vaccination, adoptive T cell therapy, NK cell therapy and dendritic cells-cytokine induced killer (DC-CIK) cell therapy are on going. In this review, the current status and future feasibility of cellular immunotherapy for leukemia are discussed.
authors.affiliation: Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, Suzhou 215006, Jiangsu Province, China.
authors.forename: Hong
authors.initials: H
authors.lastname: Tian
authors.forename: Guang-Hua
authors.initials: GH
authors.lastname: Chen
authors.forename: Yang
authors.initials: Y
authors.lastname: Xu
authors.forename: Man
authors.initials: M
authors.lastname: Qiao
authors.forename: Hui-Wen
authors.initials: HW
authors.lastname: Liu
authors.forename: De-Pei
authors.initials: DP
authors.lastname: Wu
mesh_terms: D006801:Humans; D016219:Immunotherapy, Adoptive; D007938:Leukemia / Q000628:therapy*; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology